50th Amendment to the IFRA Code of Practice
On June 30, IFRA announced the notification of the 50th Amendment to the IFRA Standards. The Standards form the basis for the globally accepted and recognized risk management system for the safe use of fragrance ingredients and are part of the IFRA Code of Practice. The amendment introduced one update to the Standards and one new prohibited substance – Mintlacton.
Marta Pinto

Marta Pinto

Regulatory Affairs Associate

FRAGRANCES, IFRA CODE OF PRACTICE AND THE NEW AMENDMENT

Fragrances are complex mixtures of aromatic substances of natural and/or synthetic origin that are added to cosmetics and personal care products to impart a pleasant and distinctive odour, mask the inherent odour of some ingredients and/or enhance the user experience of the product. However, some fragrance ingredients may have the potential to cause allergic contact skin reactions (like dermal sensitization).

It is possible to analyse these substances using a methodology called Quantitative Risk Assessment (QRA) to determine safe use levels of fragrance ingredients in a variety of consumer product types. Organizations such as the International Fragrance Association (IFRA) and the Research Institute for Fragrance Materials (RIFM) use QRA to conduct safety assessments. The International Fragrance Association (IFRA) was founded in 1973 and represents the interests of the fragrance industry worldwide. The IFRA Code of Practice is essentially the “global fragrance industry’s commitment to promoting the safe use of fragrance for everyone’s enjoyment”. Fragrance compliance means following the rules of the IFRA Code of Practice and the IFRA Standards (see previous post).

IFRA Code of Practice includes the manufacture and handling of all fragrance materials, for all types of applications. IFRA Standards form the basis for the globally accepted and recognized risk management system for the safe use of fragrance ingredients and are part of the IFRA Code of Practice. These Standards limit or ban the usage of certain fragrance materials. IFRA gathers information regarding the safety of individual fragrance ingredients and reviews that information to determine their safety under expected conditions of product use. The conclusions of the IFRA safety reviews are published in the IFRA Code of Practice which provides critical guidance to fragrance formulators and cosmetic products manufacturers. New scientific developments about analysed substances often justify amendments to the Code and Standards.

On June 30 this year (2021), the notification of the 50th amendment to the IFRA Standards was issued. According to the notification, there is only one update to the Standards and one new prohibited substance (Mintlacton – CAS No. 13341-72-5). All other elements of the 49th Amendment addressing fragrance materials remain unchanged and in place. Timelines for implementation of the prohibition of use of Mintlacton were set as follows:

  • For new creations – 2 months after the date of the notification letter;
  • For existing creations – 13 months after the date of the notification letter.

The timelines set only apply to the supply of the fragrance mixtures, not to finished products.

Fragrance manufacturers and cosmetic companies have the responsibility to ensure that the fragrances used are safe and compliant with the IFRA Code of Practice and Standards. If you need further information or support on this subject, feel free to contact us at info@criticalcatalyst.com.

References:

  1. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products.
  2. The International Fragrance Association (IFRA) – Notification of the 50th Amendment to the IFRA Standards. June 30, 2021.  
  3. The International Fragrance Association (IFRA) – Guidance for the use of IFRA Standards, 2019

further
reading

medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »